Insmed (MEX:INSM) Other Financing: MXN17,999 Mil (TTM As of Mar. 2026)


MEX:INSM Insmed Inc MEX:INSM
68 GF Score
Price MXN3,760.00
GF Value MXN5,773.42
! 4 Warning Signs
View Full Analysis

What is Insmed Other Financing?

Insmed MEX:INSM 68 Other Financing is MXN17,999 Mil as of Mar. 2026. GuruFocus rates MEX:INSM with a GF Score™ of 68/100 and a GF Value™ of MXN5,773.42. The stock has 4 warning signs investors should review.

Insmed's Other Financing for the three months ended in Mar. 2026 was MXN547 Mil.

Insmed's Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 was MXN17,999 Mil.

Insmed Other Financing Historical Data

* Premium members only.

The historical data trend for Insmed's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Insmed Other Financing Chart

Insmed Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only 129.63 2,957.95 291.64 2,283.82 2,443.68

Insmed Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 607.69 16,202.58 626.58 623.63 546.63
MEX:INSM
68GF Score
Insmed Inc MEX:INSM
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Insmed Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN17,999 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of MXN17,999 Mil mean?
Insmed (MEX:INSM) has a Other Financing of MXN17,999 Mil as of Mar. 2026. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Insmed and its competitors.
Is Insmed's Other Financing too high?
Insmed's current Other Financing is MXN17,999 Mil. Overall, Insmed has a GF Score™ of 68/100, reflecting its overall financial health beyond just this single metric.
How does Insmed's Other Financing compare to INCY and BNTX?
Insmed's Other Financing of MXN17,999 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Biotechnology company?
A good Other Financing depends on the Biotechnology industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Insmed and its competitors. Insmed's current Other Financing is MXN17,999 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Insmed stock overvalued right now?
Insmed (MEX:INSM) has a current Other Financing of MXN17,999 Mil. The stock's GF Value™ is MXN5,773.42, compared to a current price of MXN3,760.00 — trading 34.9% below its estimated fair value. The current Other Financing is MXN17,999 Mil. Insmed's overall GF Score™ is 68/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For Insmed (MEX:INSM), the current Other Financing is MXN17,999 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Insmed (MEX:INSM) Overvalued in 2026?

Based on GuruFocus' analysis, Insmed stock appears to be undervalued. The current stock price of MXN3,760.00 is trading 34.9% below its estimated GF Value™ of MXN5,773.42.

Key valuation signals for MEX:INSM:

  • Other Financing: MXN17,999 Mil
  • GF Value™: MXN5,773.42 vs. price of MXN3,760.00 (34.9% below fair value)
  • GF Score™: 68/100 with 4 warning signs

No single metric tells the full story. See the MEX:INSM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Insmed Business Description

Address 700 US Highway 202/206, Bridgewater, NJ, USA, 08807
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.
68GF Score

Get the complete analysis for MEX:INSM

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN3,760.00
Price
MXN5,773.42
GF Value